Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02263703




Registration number
NCT02263703
Ethics application status
Date submitted
3/10/2014
Date registered
13/10/2014
Date last updated
8/05/2024

Titles & IDs
Public title
Immunogenicity of HPV Vaccine in Immunosuppressed Children
Scientific title
Immunogenicity and Duration of Immunity in Immunosuppressed Children Vaccinated With Quadrivalent HPV Vaccine
Secondary ID [1] 0 0
2007/028
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Autoimmune Disease 0 0
Juvenile Idiopathic Arthritis 0 0
Inflammatory Bowel Disease 0 0
Evidence of Liver Transplantation 0 0
Kidney Transplant Infection 0 0
Bone Marrow Transplant Infection 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Quadrivalent HPV vaccine

Experimental: HPV vaccine - Quadrivalent HPV vaccine


Other interventions: Quadrivalent HPV vaccine
Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Immunogenicity
Timepoint [1] 0 0
2 years
Secondary outcome [1] 0 0
Duration of immunity
Timepoint [1] 0 0
5 years

Eligibility
Key inclusion criteria
- Immunosuppressed patients with following diseases; Bone marrow transplant recipients,
liver transplant patients, renal transplant, Children with inflammatory bowel disease,
juvenile Idiopathic arthritis and autoimmune conditions.
Minimum age
5 Years
Maximum age
18 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- A platelet count of <50

- Immunoglobulin therapy within 3 months.

- Yeast allergy

- Any other known allergies to one of the vaccine component

Study design
Purpose of the study
Prevention
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2016
Sample size
Target
Accrual to date
Final
55
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
School of Public Health and Community Medicine - Sydney
Recruitment postcode(s) [1] 0 0
2052 - Sydney

Funding & Sponsors
Primary sponsor type
Other
Name
The University of New South Wales
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Sydney Children's Hospitals Network
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Women's and Children's Hospital, Australia
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Genital HPV is the necessary cause for cervical cancer, as well as a major contributing cause
of several other cancers and conditions. There are now effective vaccines against the main
oncogenic HPV types, HPV16 and 18.

Most research and discussion has focused on targeting the vaccine to young women and older
adolescents. Based on this, a national free HPV vaccination program for adolescent girls
commenced in 2007, in Australia. However, at the time of commencement, there had been no
research on the use of this vaccine in immunosuppressed. Therefore, information on the
immunogenicity, safety and duration of efficacy of HPV vaccine when administered to
immunosuppressed children is needed. This trial looked at a 3 dose schedule of quadrivalent
HPV vaccine in a range of immunosuppressed children, with the endpoint being immunogenicity,
followed for 5 years for duration of immunity.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02263703
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Raina MacIntyre
Address 0 0
The University of New South Wales
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02263703